| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 207 | 2018 |
| Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria I Matos, J Martin-Liberal, A García-Ruiz, C Hierro, M Ochoa de Olza, ... Clinical Cancer Research 26 (8), 1846-1855, 2020 | 87 | 2020 |
| OncoTree: a cancer classification system for precision oncology R Kundra, H Zhang, R Sheridan, SJ Sirintrapun, A Wang, A Ochoa, ... JCO clinical cancer informatics 5, 221-230, 2021 | 68 | 2021 |
| A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors M Ligero, A Garcia-Ruiz, C Viaplana, G Villacampa, MV Raciti, J Landa, ... Radiology 299 (1), 109-119, 2021 | 65 | 2021 |
| Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials. I Matos, J Martin-Liberal, C Hierro, M Ochoa De Olza, C Viaplana, ... Journal of Clinical Oncology 36 (15_suppl), 3032-3032, 2018 | 46 | 2018 |
| Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification B Pellegrino, A Herencia-Ropero, A Llop-Guevara, F Pedretti, ... Cancer research 82 (8), 1646-1657, 2022 | 44 | 2022 |
| High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer M Palafox, L Monserrat, M Bellet, G Villacampa, A Gonzalez-Perez, ... Nature communications 13 (1), 5258, 2022 | 41 | 2022 |
| Analysis of mutant allele fractions in driver genes in colorectal cancer–biological and clinical insights R Dienstmann, E Elez, G Argiles, I Matos, E Sanz‐Garcia, C Ortiz, ... Molecular oncology 11 (9), 1263-1272, 2017 | 33 | 2017 |
| Evolving landscape of molecular prescreening strategies for oncology early clinical trials R Dienstmann, E Garralda, S Aguilar, G Sala, C Viaplana, F Ruiz-Pace, ... JCO Precision Oncology 4, 505-513, 2020 | 17 | 2020 |
| High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer M Sánchez-Guixé, C Hierro, J Jiménez, C Viaplana, G Villacampa, ... Clinical Cancer Research 28 (1), 137-149, 2022 | 14 | 2022 |
| PI3K activation promotes resistance to eribulin in HER2-negative breast cancer A Gris-Oliver, YH Ibrahim, MA Rivas, C García-García, M Sánchez-Guixé, ... British Journal of Cancer 124 (9), 1581-1591, 2021 | 13 | 2021 |
| Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients S Cedrés, S Ponce-Aix, P Iranzo, A Callejo, N Pardo, A Navarro, ... Clinical and Translational Oncology 22, 1390-1398, 2020 | 12 | 2020 |
| A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018 M Castroviejo-Bermejo, C Cruz, A Llop-Guevara, S Gutiérrez-Enríquez, ... Article e9172 View in Scopus, 2018 | 12 | 2018 |
| Early-stage breast cancer detection in breast milk C Saura, C Ortiz, J Matito, EJ Arenas, A Suñol, Á Martín, O Córdoba, ... Cancer discovery 13 (10), 2180-2191, 2023 | 9 | 2023 |
| Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials. V Rodriguez Freixinos, A Garcia, R Fasani, J Castellvi, F Ruiz-Pace, ... Journal of Clinical Oncology 36 (15_suppl), 5595-5595, 2018 | 8 | 2018 |
| Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability IM Garcia, AG Ruiz, J Martin-Liberal, C Hierro, MODO Amat, C Viaplana, ... Annals of Oncology 29, viii653, 2018 | 5 | 2018 |
| Artificial intelligence combining radiomics and clinical data for predicting response to immunotherapy M Ligero, A Garcia-Ruiz, C Viaplana, MV Raciti, I Matos, JM Liberal, ... Annals of Oncology 30, v476, 2019 | 3 | 2019 |
| Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials I Matos, G Villacampa, C Hierro, J Martin-Liberal, R Berché, A Pedrola, ... European Journal of Cancer 155, 168-178, 2021 | 2 | 2021 |
| 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer F Brasó-Maristany, M Palafox, L Monserrat, M Bellet, M Oliveira, ... Annals of Oncology 32, S27, 2021 | 2 | 2021 |
| Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune … IM Garcia, A Azaro, C Viaplana, C Hierro, J Martin-Liberal, I Brana, ... Annals of Oncology 29, viii35, 2018 | 2 | 2018 |
